ACTI ON OF N- ACETYLCYSTEI NE ON ASYMMETRI C DIMETHYLARGININE AND ALBUMINURIA IN STAGE 1-4 NONDIABETIC CHRONIC KIDNEY DISEASE PATIENTS
Downloads
Background: Uremic patients are in a pro-oxidant state and show an increased level of asymmetric dimethylarginine (ADMA), which is due to increased PRMT1 activity and reduced dimethylarginine dimethylaminohydrolase (DDAH) as degradation enzymes. Reactive oxidant species may play an important role in increasing the action of PRMT1 and in inhibiting the action of DDAH. Albuminuria and ADMA are closely correlated with progression of cardiovascular disease in chronic kidney disease (CKD) patients
as well as indicators for decreasing renal function. Although ACEIs and/or ARBs reduced albuminuria in CKD patients, the results are still conflicting. Several factors in these patients may play important roles in the mechanism of albuminuria such as oxidative
stress. The antioxidant N-acetylcysteine may prove to have beneficial therapeutic effect, because it can reduce oxidative stress as shown by evidence in humans, and subsequently increase ADMA. The objective of the present study is to explore the contribution
of the antioxidant N-acetylcysteine (NAC) to the decrease of ADMA and albuminuria in non-diabetic CKD patients. Material and Methods: Patients with non-DM CKD stage 1–4 with albuminuria were randomized to receive ACEI and/or ARB alone (control group) or with antioxidant NAC 600 mg orally twice a day (treatment group). Observations were performed for 3 months to measure ADMA and albuminuria before and after-treatment. 80 patients in total 40 in the control group and 40 in the treatment group were used. Results: After oral treatment with NAC, the plasma level of ADMA in the treatment group increased from 0.604 µmol/l to 0.689 µmol/l, whereas ADMA level in the control group exhibited a higher increase from 0.561 µmol/l to 0.743 µmol/l. The increases in these groups were significantly different (p < 0.02). Moreover, the level of albuminuria was reduced from 148.12 µg/mg • cr to 132.7 µg/mg • cr in the treatment group, and from 75.25 µg/mg • cr to 71.85 µg/mg • cr in the control group. The difference was significant (p < 0.001). Conclusion: The anti-oxidant N-acetylcysteine can be used as adjuvant therapy to inhibit the progression of CKD in patients by decreasing the ADMA level and albuminuria.
2. Cooke JP, Dzau VJ. Derangements of the nitric oxide synthase
pathway, L-arginine, and cardiovascular diseases. Circulation. 1997;
96: 379–382.
3. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997; 100: 2153–2157.
4. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler
Thromb Vasc Biol. 2000; 20: 2032–2037.
5. Ueda S, Yamagishi S, Kaida Y, Okuda S. Asymmetric dimethylarginine (ADMA) may be a missing link between chronic kidney disease (CKD) and cardiovascular disease (CVD). Nephrology. 2007; 12: 582–590.
6. Cooke PJ. Asymetrical Dimethylarginine, The Uber Marker? USA:
American Heart Association; 2004. Halaman 1813–1818.
7. Baylis C. Arginine, Arginine Analogs and Nitric Oxide Production
in Chronic Kidney Disease. Nature Clinical Practice Nephrology.
2006; 2(4): 209–20.
8. Caglar K, Yilmaz MI, Sonmez A, et al. ADMA, proteinuria, and
insulin resistance in non-diabetic stage I chronic kidney disease.
Kidney Int. 2006; 70: 781–787.
9. Kielstein JT, Martens-Lobenhoffer J, Vollmer S, Bode-Boger SM.
L-Arginine, ADMA, SDMA, creatinine, MDRD formula: detour to
renal function testing. J Nephrol. 2008; 21: 959–961.
10. Panichi V, Mantuano E, Paoletti S, et al. Effect of simvastatin on
plasma asymmetric dimethylarginine concentration in patients with
chronic kidney disease. J Nephrol. 2008; 21: 38–44.
11. Boger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res. 2000; 87: 99–105.
12. Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation
of dimethylarginine dimethylaminohydrolase regulates enzyme
activity: further interactions between nitric oxide synthase and
dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA.
2002; 99: 13527–13532.
13. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002; 62: 1524–1538.
14. Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol. 2004; 15 Suppl 1: S77–S80.
15. Locatelli F. Oxidative Stress in End-Stage Renal Disease: An
Emerging Threat to Patient Outcome. Nephrology Dialysis
Transplantation. 2003; 18: 1272–1280.
16. Araujo M, and Welch, J.M. Oxidative Stress and Nitrite Oxide in
Kidney Function. Current Opinion Nephrology and Hypertension.
2006; 15: 72–77.
17. Cooke JP. Does ADMA Cause Endothelial Dysfunction?
Arteriosclerosis Thrombosis Vascular Biology. 2000; 20: 2032–7.
18. Jafar. Proteinuria as Modifiable Risk Factor for the Progression of
Non Diabetic Renal Disease. Kidney Internal. 2001; 67: 2288–94.
19. Lea. The Magnitude Between Proteinuria Reduction and Risk End
Stage Renal Disease. Archive Internal Medicine. 2005; 163.
20. Ivanovski O, et al. The Antioxidant N-Acetylcysteine Prevents
Accelerated Atherosclerosis in Uremic Apolipoprotein E Knockout
Mice. Kidney Int. 2005; 67: 2288–94.
21. Schulze, et al. Determination of Asymetric Dimethylarginine
(ADMA) using a Novel ELISA Assay. Clin Chem Lab Med. 2004; 42(12): 1377–1383.
22. Thaha M, Yogiantoro M, Tomino Y. Intravenous N – Acetylcysteine during Hemodialysis Reduces the Plasma Concentration of Homocysteine in Patients with End Stage Renal Disease. Clin Drug Invest. 2006; 26(4): 195–202.
23. Yuli H. Pengaruh Pemberian N-Asetilsistein Intravena terhadap
Kadar Adma pada Pasien Penyakit Ginjal Kronik Stadium 5 Selama
Tindakan Hemodialisis. SMF Penyakit Dalam, RSU Dr. Soetomo.
2006.
24. Kielstein JT, Boger RH, Bode-Boger SM, et al. sMarked increase
of asymmetric dimethylarginine in patients with incipient primary
chronic renal disease. J Am Soc Nephrol. 2002; 13: 170–176.
25. Yilmaz, et al. ADMA Levels Correlate with Proteinuria, Secondary Amyloidosis, and Endothelial Dysfunction. J Am Soc Nephrol. 2008;19: 388–395
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
